A.P. Pharma, Inc. — Form 10-Q Summary
Filing identity: The provided filing is for A.P. Pharma, Inc., not Heron Therapeutics, Inc. Investors should verify the issuer and filing metadata.
Business Context and Reporting Period
The filing covers the unaudited quarter ended March 31, 2013, compared with the quarter ended March 31, 2012. A.P. Pharma was a specialty pharmaceutical company developing injectable drug-delivery products using its Biochronomer platform. Its lead candidate, APF530, contained granisetron and was being developed to prevent chemotherapy-induced nausea and vomiting.
On March 28, 2013, the FDA issued a Complete Response Letter identifying issues that prevented approval of the APF530 NDA in its current form. Management stated that it believed the issues were addressable and intended to resubmit the NDA.
Financial Highlights
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | — |
| Research and development expense | $6.8 million | $3.3 million | +$3.5 million |
| General and administrative expense | $6.0 million | $1.4 million | +$4.6 million |
| Total operating expenses | $12.8 million | $4.8 million | +$8.0 million |
| Operating loss | $12.8 million | $4.8 million | Loss increased |
| Net loss | $13.0 million | $4.9 million | Loss increased by $8.0 million |
| Net loss per share | $0.04 | $0.02 | Loss per share increased |
| Cash used in operating activities | $8.0 million | $4.1 million | Use increased by $3.9 million |
| Capital expenditures | $0.4 million | $0.4 million | Broadly unchanged |
There was no reported product revenue, and the company remained dependent on financing and cash reserves. Interest expense was $0.2 million, compared with $0.1 million in the prior-year quarter.
Balance Sheet, Debt, and Liquidity
- Cash and cash equivalents were $45.7 million at March 31, 2013, down from $53.5 million at December 31, 2012.
- Total assets were $49.0 million, compared with $56.0 million at year-end 2012.
- Current liabilities were $7.6 million, compared with $4.2 million at December 31, 2012.
- Accumulated deficit was $196.5 million at March 31, 2013.
- Convertible notes had approximately $4.8 million of principal outstanding and a $0.6 million carrying value after debt discount. The notes bear interest at 6%, mature in 2021, are secured by substantially all company assets, and may be subject to holder-requested prepayment.
- Management stated that available cash was sufficient to fund planned operations into 2014, but additional capital could be required depending on regulatory, manufacturing, commercialization, and development costs.
- The company reported no off-balance-sheet arrangements and compliance with its debt covenants as of March 31, 2013.
Material Changes Versus the Prior Comparable Period
- Research and development expense more than doubled, primarily because of higher headcount, APF530 project spending, manufacturing-process validation, and production scale-up.
- General and administrative expense increased substantially because of higher headcount-related costs, stock-based compensation, market research, consulting, professional fees, and pre-commercialization activities.
- Stock-based compensation increased to $1.8 million from $0.8 million, primarily reflecting higher general and administrative expense.
- Net cash used in operations nearly doubled to $8.0 million from $4.1 million, mainly due to the larger operating loss.
- Financing activities provided $0.6 million in Q1 2013 from warrant and stock-option exercises; no financing cash was provided in Q1 2012.
- Loss from discontinued operations was zero in Q1 2013 versus $0.1 million in Q1 2012. The related gross-profit-guaranty dispute was resolved in February 2013, and the company had reversed a previously recorded $1.1 million accrual as of December 31, 2012.
Guidance, Outlook, Risks, and Unusual Items
- Management expected 2013 research and development expense to exceed 2012 levels because of manufacturing expenses and work addressing the FDA Complete Response Letter.
- Management expected 2013 general and administrative expense to exceed 2012 levels because of NDA-resubmission support and a full year of pre-commercialization activity.
- The timing and likelihood of APF530 approval and commercial launch remained uncertain following the FDA’s Complete Response Letter.
- Key risks included the cost and outcome of NDA resubmission, manufacturing readiness, market acceptance, competition, the need for additional financing, potential shareholder dilution, and the company’s ability to establish commercial infrastructure.
- Contractual obligations totaled approximately $3.9 million, consisting of $2.9 million of operating lease obligations and $1.0 million of purchase commitments; $1.9 million was due within one year.
- Subsequent to quarter-end, the company announced new executive leadership effective May 2013, including Barry D. Quart as chief executive officer, Robert Rosen as president, and Stephen R. Davis as chief operating officer.
- Management reported that disclosure controls and procedures were effective as of March 31, 2013, with no significant changes in internal control over financial reporting.
Investor Verification Checklist
- Verify that the filing belongs to A.P. Pharma, Inc. and not Heron Therapeutics, Inc.
- Review the FDA Complete Response Letter and the specific deficiencies that must be addressed before APF530 approval.
- Assess the company’s cash runway against its stated ability to fund operations into 2014 and likely NDA, manufacturing, and commercialization costs.
- Review the terms and potential prepayment requirements of the secured convertible notes.
- Evaluate dilution from approximately 89.2 million options, 81.0 million warrants, and 120.3 million shares underlying convertible notes.
- Confirm the treatment and final resolution of the discontinued-business gross-profit guaranty.